24Mar

BBI Solutions & Dr C. Sturgeon consider International Standards for Cancer Biomarkers

Dr Catharine Sturgeon will be presenting her case for an international effort to align manufacturer’s assays for CA125, CA19-9 and other mucinous markers in a webinar. Organised by BBI Solutions, a leading manufacturer of raw materials and finished test platforms for the in-vitro diagnostics market, the webinar will cover benefits of tumour marker standardisation and discuss how tumour marker standardisation can be improved.

Dr Sturgeon is a Consultant Clinical Scientist and Director of the UK NEQAS unit at the Royal Infirmary of Edinburgh. She has a particular interest in tumour markers and has worked to encourage their appropriate use through implementation of practice guidelines, such as those of the European Group on Tumour Markers and the National Academy of Clinical Biochemistry. Catharine has a long-standing interest in improving both analytical quality and clinical interpretation of laboratory tests. She has been actively involved in several standardisation projects, including those of the IFCC Working Groups on hCG and growth hormone.

International Standards (IS) and International Reference Preparations help to improve between-laboratory comparability of immunoassay results and can also enable better understanding of what is being measured. The ‘good agreement’ between results observed for AFP and PSA markers reflects the availability of appropriately constituted International Standards for these important tumour markers. Those for hCG are also contributing to optimal design of the next generation of hCG immunoassays. However, there are, as yet, no International Standards for CA125, CA19-9 and other mucinous markers for which between-method agreement is poor.

In the webinar, Dr. Catharine Sturgeon will consider why this is the case and what collaborative international initiatives are required to fill the gap.

The webinar titled: Standardisation of serum tumour markers – optional extra or essential? Is on Tuesday 4th April 2017, 3pm BST. Spaces are limited so reserve your place today by following this link: www.bbisolutions.com/webinar.

Related

On World Cancer Day, Global Good and QuantuMDx Partner to Combat Cervical Cancer

Newcastle upon Tyne, UK – [February 2, 2017] – QuantuMDx Group announced an assay co-development a...

Read More >

Protect Your Samples from Acidification When Shipped On Dry Ice

The new ProtectR® tubes, now available from Alpha Laboratories, have the only container closure syst...

Read More >

AMLo Biosciences raises £2.45m to further develop early stage skin cancer test

AMLo Biosciences Ltd (AMLo), an innovative medical device company spun out of Newcastle University s...

Read More >

EKF introduces mobile data management solution for the DiaSpect Tm POC hemoglobin analyzer

Cardiff, UK – 13th November 2017 – EKF Diagnostics, the global in vitro diagnostics company, today...

Read More >

EKF signs DiaSpect Tm U.S. distribution agreement with McKesson to launch McKesson Consult® Hb analyzer

FDA cleared POC hemoglobin analyzer to be sold across the USA by the market’s leading and most esta...

Read More >

Radiometer helps enhance patient outcomes at the University of Leicester Hospitals NHS Trust

Crawley, UK – 15 February 2018 – Radiometer Ltd has implemented its AQURE Enterprise point-of-care...

Read More >